USPTO Examiner ANTHOPOLOS PETER - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19022909SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEJanuary 2025March 2025Allow200YesNo
18785092IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18785063IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEJuly 2024September 2024Allow200YesNo
18759349VIGABATRIN LIQUID PHARMACEUTICAL COMPOSITIONJune 2024March 2025Allow910YesNo
18665149SLEEP-IMPROVING COMPOSITIONS AND METHODS OF USEMay 2024December 2024Allow710YesNo
18643713PARENTERAL NUTRITION CONTAINING TRACE ELEMENTSApril 2024March 2025Abandon1111NoNo
18627020SHEET-SHAPED MEMBERApril 2024June 2025Abandon1510NoNo
18542993COSMETIC COMPOSITIONS AND METHODS OF USEDecember 2023September 2024Allow900YesNo
18487486Compositions Having Improved Bioavailability of TherapeuticsOctober 2023December 2024Allow1421YesNo
18369616DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODYSeptember 2023May 2025Abandon1901NoNo
18206559Method of improving psychosocial healthJune 2023June 2024Allow1321YesNo
18312375IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEMay 2023June 2024Allow1321NoNo
18312333IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEMay 2023March 2024Allow1011YesNo
18122478THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSESMarch 2023March 2024Allow1221YesNo
18175495AFFINITY ILLUDOFULVENE CONJUGATESFebruary 2023December 2024Allow2120NoNo
18112747MAIN AGENT UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEFebruary 2023December 2024Abandon2210NoNo
18100821COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLESJanuary 2023June 2024Allow1721YesNo
18091176SHEET-SHAPED MEMBERDecember 2022December 2023Allow1110NoNo
18086725COSMETIC COMPOSITIONS AND METHODS OF USEDecember 2022September 2023Allow900NoNo
18082311MEDICAL COUNTER MEASURES INCLUDING DRY POWDER FORMULATIONS AND ASSOCIATED METHODSDecember 2022March 2024Allow1511YesNo
18076012LIQUID FORMULATION COMPOSITIONS, MEDICAMENT DELIVERY DEVICES, AND METHODS OF PREPARATION AND USE THEREOFDecember 2022April 2025Abandon2801NoNo
18047375MICROENCAPSULATION OF NICOTINE FOR TOBACCOLESS ORAL ADMINISTRATIONOctober 2022March 2024Abandon1721NoNo
17957640DIMETHYLTRIPTAMINE-BASED NASAL SPRAY FOR THE PERSONALISED TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERSSeptember 2022March 2025Abandon2910NoNo
17902742COMPOSITION FOR COSMETICSSeptember 2022August 2023Abandon1211NoNo
17823239INHALABLE ANTIMICROBIAL PARTICLES AND METHODS OF MAKING THE SAMEAugust 2022March 2023Allow600YesNo
17821833IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONEAugust 2022February 2023Allow610YesNo
17871921BUFFER-FREE OPHTHALMOLOGICAL COMPOSITIONS OF KETOROLAC AND PHENYLEPHRINE AND APPLICATIONS THEREOFJuly 2022September 2023Allow1420YesNo
17856600Therapeutic Textile Articles and Methods of UseJuly 2022September 2024Allow2711YesNo
17841813HIGH STRENGTH BIOMEDICAL MATERIALSJune 2022March 2025Allow3310YesNo
17842187METHOD OF PREPARING BIOACTIVE SUBSTANCE-ENCAPSULATED ETHOSOME, ETHOSOME COMPOSITION, AND COSMETIC COMPOSITION INCLUDING ETHOSOME COMPOSITIONJune 2022August 2024Abandon2610NoNo
17838866PREPARATIONS FOR CONTROLLED-RELEASE OF HYPOCHLOROUS ACIDJune 2022September 2024Allow2711NoNo
17830813Mesh Compositions and Methods of ProductionJune 2022July 2024Abandon2610NoNo
17733216TREATMENT OF GLAUCOMA USING ENDOTHELIN RECEPTOR ANTAGONISTSApril 2022June 2023Allow1421YesNo
17720595MICROBIAL OIL, PRODUCTION METHOD FOR MICROBIAL OIL, CONCENTRATED MICROBIAL OIL, AND PRODUCTION METHOD FOR CONCENTRATED MICROBIAL OILApril 2022August 2023Allow1600NoNo
17669781COMPOSITIONS COMPRISING CHOLINEFebruary 2022December 2023Abandon2201NoNo
17557108ANTISEPTIC POLYMER AND SYNTHESIS THEREOFDecember 2021September 2023Allow2111YesNo
17547712THERAPEUTIC MATERIAL WITH LOW pH AND LOW TOXICITY ACTIVE AGAINST AT LEAST ONE PATHOGEN FOR ADDRESSING PATIENTS WITH RESPIRATORY ILLNESSESDecember 2021December 2022Allow1221YesNo
17545331Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin DiseasesDecember 2021March 2025Allow3920NoNo
17617470Device in the Form of a Cannabinoid-Based Polymer MatrixDecember 2021February 2025Abandon3811NoNo
17457792PARASITICIDAL COLLAR COMPRISING ISOXAZOLINE COMPOUNDSDecember 2021August 2024Allow3321YesNo
17540277Enhanced Rodeferin Broad SpectrumDecember 2021March 2023Abandon1611NoNo
17539726FASTING-MIMICKING DIET PROMOTES CANCER-FREE SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA MODELSDecember 2021December 2024Allow3721NoNo
17534292Stimulation of NK Cell Activity by Using a Combination of Broccoli, Nigella Sativa, Green Tea, and Pterostilbene Alone and Together with MetforminNovember 2021February 2024Allow2720NoNo
17515322PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF COVID- 19 INFECTIONOctober 2021August 2022Allow1010NoNo
17607175NEW DELIVERY SYSTEM FOR FAT SOLUBLE VITAMINSOctober 2021May 2025Allow4331YesNo
17510829MODIFIED RELEASE COATED CAPSULESOctober 2021March 2024Allow2821YesNo
17602052COMPOSITION FOR USE IN IMPROVING ENDOTHELIAL FUNCTION BY ENHANCING FLOW MEDIATED DILATIONOctober 2021June 2025Allow4411YesNo
17493949ORAL AMPHETAMINE COMPOSITIONOctober 2021October 2023Allow2411YesNo
17485995Phenylethanoid Glycoside Extract from Acanthus Ilicifolius L., Preparation Method thereof and Use as Anti-liver Injury MedicamentSeptember 2021June 2025Allow4411NoNo
17483070IMMEDIATE RELEASE PHARMACEUTICAL FORMULATION OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONESeptember 2021January 2024Abandon2821NoNo
17440009SAPONIN-BASED VACCINE ADJUVANTSSeptember 2021May 2025Allow4421NoNo
17472611DI-ISOPROPYL-PHOSPHINOYL-ALKANES (DAPA) COMPOUNDS AS TOPICAL AGENTS FOR THE TREATMENT OF SENSORY DISCOMFORTSeptember 2021April 2023Allow1930NoNo
17447101VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALINGSeptember 2021January 2025Allow4021YesNo
17410900PHARMACEUTICAL FORMULATION OF ARSENIC TRIOXIDEAugust 2021December 2022Allow1621YesNo
17397256ALKENONE-BASED FORMULATIONS FOR TOPICAL APPLICATIONSAugust 2021August 2023Allow2421NoNo
17444041USE OF RIVASTIGMINE IN PREPARATION OF ANTI-RADIATION MEDICAMENTJuly 2021June 2023Allow2311NoNo
17372436LIQUID FORMULATION COMPOSITIONS, MEDICAMENT DELIVERY DEVICES, AND METHODS OF PREPARATION AND USE THEREOFJuly 2021October 2022Allow1500YesNo
17365692PARENTERAL NUTRITION CONTAINING TRACE ELEMENTSJuly 2021April 2025Abandon4552YesYes
17362204TOPICAL VITAMIN C COMPOSITIONJune 2021March 2025Allow4541YesNo
17338882COMPOSITIONS INCLUDING GINSENOSIDE 20(S)-Rg3 AND METHODS OF USING GINSENOSIDE 20(S)-Rg3 TO INHIBIT ALPHA HERPESVIRUSJune 2021January 2024Allow3121YesNo
17296200NANOPARTICLES CONTAINING CELLULAR MEMBRANE AND USES THEREOFMay 2021March 2025Allow4531NoNo
17327234NANO-PENETRATIVE CANNABINOID OIL BLENDS AND COMPOSITIONS AND METHODS OF FORMULATION THEREOFMay 2021October 2022Abandon1721NoNo
17324752COMPOSITIONS OF CARDIOLIPIN ADJUVANTS AND METHODS OF USE THEREOFMay 2021July 2023Allow2611NoNo
17285868TLR9 AGONISTS FOR USE IN DOWNREGULATING CLEVER-I EXPRESSION ON ALTERNATIVELY ACTIVATED MACROPHAGESApril 2021January 2025Abandon4501NoNo
17229693DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODYApril 2021September 2023Abandon2911NoNo
17226049Composition for A Nutraceutical Formulation for Treating Anxiety-Based DisordersApril 2021July 2023Abandon2810NoNo
17212408COMPOSITIONS FOR MAINTAINING ELECTROLYTE BALANCE AND URINARY TRACT HEALTHMarch 2021September 2023Abandon2911NoNo
17189309SURFACE-MODIFIED EMULSOMES FOR INTRANASAL DELIVERY OF DRUGSMarch 2021September 2021Allow711YesNo
17271071COMPOUNDS AND COMPOSITIONS FOR POTENTIATION OF TLR AGONISTSFebruary 2021September 2024Abandon4210NoNo
17181914ANTICANCER PEPTIDES THAT SYNERGISTICALLY ENHANCE CHEMOTHERAPEUTIC POTENCYFebruary 2021June 2022Allow1600YesNo
17180784Method Of Treating, Reducing, Or Alleviating A Medical Condition In A PatientFebruary 2021January 2023Allow2241YesNo
17269002A MAIN AGENT UNIFORMLY DISPERSED MICROSPHERE AND A SUSTAINED RELEASE FORMULATION COMPRISING THE SAMEFebruary 2021November 2022Allow2131YesNo
17172455COMPOSITIONS AND METHODS FOR CONTROLLED DELIVERY OF VOLATILE VAPORSFebruary 2021February 2023Allow2441NoNo
17248581PHARMACEUTICAL COMPOSITION COMPRISING LICARBAZEPINE ACETATEJanuary 2021August 2023Abandon3020NoNo
17157107COMPOSITION FOR THE TREATMENT OF COVID-19January 2021October 2024Allow4540YesNo
17135143Therapeutic Textile Articles and Methods of UseDecember 2020August 2021Allow801NoNo
16969092COMPOSITION FOR INCREASING THE EXPRESSION OF A GROWTH FACTOR GENE, COMPRISING CORESHELL STRUCTURED MICROPARTICLES AS ACTIVE INGREDIENTDecember 2020December 2024Allow5222YesNo
17125591PHARMACEUTICAL COMPOSITION CONTAINING ANTIFUNGAL AGENT AS ACTIVE INGREDIENTDecember 2020June 2023Allow3020NoNo
17119734PHARMACEUTICAL AND NUTRITIONAL COMPOSITION TO MAXIMIZE NAD ENZYME'S HEALTH BENEFITSDecember 2020December 2023Abandon3611NoNo
17113966PHARMACEUTICAL FORMULATION OF ODEVIXIBATDecember 2020April 2023Allow2851YesNo
17104055SURFACE-MODIFIED EMULSOMES FOR INTRANASAL DELIVERY OF DRUGSNovember 2020June 2021Allow611YesNo
17103780AFFINITY ILLUDOFULVENE CONJUGATESNovember 2020October 2022Allow2351NoNo
17058574Vitamin Cationic LipidsNovember 2020October 2024Allow4711YesNo
17055250Cationic Peptides for Activating LckNovember 2020June 2024Allow4311NoNo
17049062COMPOSITIONS, METHODS, SYSTEMS TO ADDRESS STRESS, STARVATION, IMPROVED HEALTH, IMPROVED WATER QUALITY, PRODUCTIVITY AND LIFE EXPECTANCY OF FISHESOctober 2020May 2024Abandon4310NoNo
17073656DUAL-SCALE POROUS SILICA PARTICLE-BASED COMPOSITION FOR PREVENTING OR TREATING CANCEROctober 2020November 2023Allow3721YesNo
17067253PHOSPHATE COMPOSITIONS WITH A LOW ALUMINUM CONTENTOctober 2020June 2021Allow811YesNo
17064390Elastic Biopolymer and Use as a Tissue AdhesiveOctober 2020May 2024Allow4321YesNo
17042988MOLECULES HAVING PESTICIDAL UTILITY, AND INTERMEDIATES, COMPOSITIONS, AND PROCESSES, RELATED THERETOSeptember 2020March 2024Abandon4101NoNo
17041099MODIFIED CYCLIC DINUCLEOTIDE COMPOUNDSSeptember 2020May 2024Abandon4410NoNo
17028838METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING TRICHOMONIASIS AND USES THEREOFSeptember 2020February 2025Allow5241NoNo
16981344CARMUSTINE FORMULATIONSeptember 2020June 2025Allow5722YesNo
17014774COMPOUNDS AND PHARMACEUTICAL USES THEREOFSeptember 2020May 2021Allow811YesNo
16978037Compositions and Methods for Treating Hyperproliferative Skin DisordersSeptember 2020April 2023Allow3221YesNo
17009423IMMUNOMODULATOR COMPOUNDS AND METHODS OF USESeptember 2020April 2025Abandon5521YesNo
16966368LIPID-LIKE NANOCOMPLEXES AND USES THEREOFJuly 2020June 2024Allow4621YesNo
16873767Method to reduce face mask and respirator discomfortJune 2020March 2022Allow2100YesNo
16907086TREATMENT AND PREVENTION OF THE COMMON COLD USING POVIDONE-IODINEJune 2020December 2022Abandon3011NoNo
16900268CARBON-POLYMER COMPLEXJune 2020August 2022Allow2610NoNo
16893532FOAM FORMULATIONS AND APPARATUS FOR DELIVERYJune 2020June 2025Allow6091YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ANTHOPOLOS, PETER.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
11
Examiner Affirmed
7
(63.6%)
Examiner Reversed
4
(36.4%)
Reversal Percentile
56.3%
Higher than average

What This Means

With a 36.4% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
40
Allowed After Appeal Filing
6
(15.0%)
Not Allowed After Appeal Filing
34
(85.0%)
Filing Benefit Percentile
15.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 15.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ANTHOPOLOS, PETER - Prosecution Strategy Guide

Executive Summary

Examiner ANTHOPOLOS, PETER works in Art Unit 1611 and has examined 530 patent applications in our dataset. With an allowance rate of 54.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner ANTHOPOLOS, PETER's allowance rate of 54.9% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ANTHOPOLOS, PETER receive 2.32 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ANTHOPOLOS, PETER is 35 months. This places the examiner in the 19% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +61.3% benefit to allowance rate for applications examined by ANTHOPOLOS, PETER. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.3% of applications are subsequently allowed. This success rate is in the 26% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 16.3% of cases where such amendments are filed. This entry rate is in the 11% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 35% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 39.6% are granted (fully or in part). This grant rate is in the 38% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.2% of allowed cases (in the 49% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.